Tabriz University of Medical Sciences Advanced Pharmaceutical Bulletin 2228-5881 12 2 2022 03 09 Mesenchymal Stem Cells in the Treatment of New Coronavirus Pandemic: A Novel Promising Therapeutic Approach 206 216 10.34172/apb.2022.023 EN Sara Razi https://orcid.org/0000-0001-9592-9549 Zahra Molavi Seyed Amir Mirmotalebisohi Zahra Niknam Marzieh Sameni Vahid Niazi Amirjafar Adibi Mohsen Yazdani Mohammad Mehdi Ranjbar Hakimeh Zali https://orcid.org/0000-0003-2770-5759 EDITORIAL 10.34172/apb.2022.023 2020 08 29 2021 03 25 After severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks, coronavirus disease 2019 (COVID-19) is the third coronavirus epidemic that soon turned into a pandemic. This virus causes acute respiratory syndrome in infected people. The mortality rate of SARS-CoV-2 infection will probably rise unless efficient treatments or vaccines are developed. The global funding and medical communities have started performing more than five hundred clinical examinations on a broad spectrum of repurposed drugs to acquire effective treatments. Besides, other novel treatment approaches have also recently emerged, including cellular host-directed therapies. They counteract the unwanted responses of the host immune system that led to the severe pathogenesis of SARS-CoV-2. This brief review focuses on mesenchymal stem cell (MSC) principles in treating the COVID-19. The US clinical trials database and the world health organization database for clinical trials have reported 82 clinical trials (altogether) exploring the effects of MSCs in COVID-19 treatment. MSCs also had better be tried for treating other pathogens worldwide. MSC treatment may have the potential to end the high mortality rate of COVID-19. Besides, it also limits the long-term inability of survivors.